4-甲氧基-7-甲基茚满 | 175136-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 4-甲氧基-7-甲基茚满
• 英文名称: 4-methoxy-7-methylindane
• 英文别名: 4-methoxy-7-methyl-2,3-dihydro-1H-indene
• CAS: 175136-08-0
• 化学式: C₁₁H₁₄O
• mdl: MFCD00173679
• 分子量: 162.232
• InChiKey: WLLDRYXQMFGAKW-UHFFFAOYSA-N

物化性质

• 沸点：
  268.8±29.0 °C(Predicted)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

文献信息

• [EN] SUBSTITUTED PYRAZINE DERIVATIVES<br/>[FR] DERIVES PYRAZINIQUES SUBSTITUES
  申请人：UPJOHN CO

  公开号：WO2003091225A1

  公开（公告）日：2003-11-06

  The present invention provides substituted pyrazine derivatives of Formula (I), that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

  本发明提供了式（I）的取代吡嗪衍生物，其为CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及利用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是与焦虑有关的疾病和情绪障碍。
• [EN] COMPOSITION AND METHOD FOR INFLUENCING ENERGY METABOLISM AND TREATING METABOLIC AND OTHER DISORDERS<br/>[FR] COMPOSITION ET PROCÉDÉ POUR INFLUENCER LE MÉTABOLISME ÉNERGÉTIQUE ET TRAITER DES TROUBLES MÉTABOLIQUES ET D'AUTRES TROUBLES
  申请人：SIRTUIN VALLEY OY

  公开号：WO2012056113A1

  公开（公告）日：2012-05-03

  A composition and method for influencing energy metabolism and treating metabolic and other disorders is provided. A terpenoid lactone that is a selective activator of SIRT1 is generally in the form of a terpenoid dilactone having a 5-alkenyloxy-furan-2- one group, such as strigolactone, GR 24, or another strigolactone analog, and is used as a therapeutic agent in a method for influencing energy metabolism and treating metabolic and other disorders. The terpenoid lactone may be administered as an individual agent or combined with a second compound such as a flavonoid, chalconoid, tannin, or nicotinamide inhibition antagonist.

  提供了一种影响能量代谢和治疗代谢和其他疾病的组合物和方法。一种选择性激活SIRT1的萜类内酯酮通常以一种萜类二内酯的形式存在，具有5-烯氧基呋喃-2-酮基团，如赤露内酯、GR 24或另一种赤露内酯类似物，并且用作影响能量代谢和治疗代谢和其他疾病的治疗剂的方法中。萜类内酯酮可以作为单独的药剂给药，也可以与第二化合物（如黄酮类、香豆素类、单宁或烟酰胺抑制拮抗剂）结合给药。
• Substituted pyrazine derivatives
  申请人：——

  公开号：US20040053941A1

  公开（公告）日：2004-03-18

  The present invention provides substituted pyrazine derivatives of Formula I, 1 that are CRF 1 receptor antagonists, including human CRF 1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

  本发明提供了式I,1的取代吡嗪衍生物，它们是CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及使用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是焦虑相关疾病和情绪障碍。
• SUBSTITUTED PYRAZINE DERIVATIVES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1499599A1

  公开（公告）日：2005-01-26
• COMPOSITION AND METHOD FOR INFLUENCING ENERGY METABOLISM AND TREATING METABOLIC AND OTHER DISORDERS
  申请人：Sirtuin Valley Oy

  公开号：EP2632456A1

  公开（公告）日：2013-09-04